

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF **MILIND RAJOPADHYE, ET AL**

FOR: **VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS**

APPLICATION NO: **09/599890**

APPLICATION DATE: **6/21/2000**

ART UNIT: **1624**

EXAMINER: **BALASUBRAMANIAN, VENKATARAMAN**

CONFIRMATION NO: **7176**

USPTO CUSTOMER NO: **46339**

VIA EFS WEB

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**AMENDMENT AFTER ALLOWANCE UNDER 37 C.F.R. §1.312**

Sir:

Applicants which to submit this amendment after allowance to make of record the following amendments to the specification. Should there be any incurred fees with the submission of this response, the Commissioner is hereby authorized to charge the additional fees under 37 CFR 1.17 which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Amendments to the Specification:

Please amend this application as follows.